Beijing Sun-Novo Pharmaceutical Research (688621.SH): ABA001 injection received approval for clinical trials of pharmaceuticals
Sunshine Pharmaceutical Co., Ltd. (688621.SH) announced that the company and its wholly-owned subsidiary, Beijing Alna Technology Co., Ltd., have received the "Notice of Approval for Clinical Trial of Drugs" issued by the State Food and Drug Administration. The company's application for clinical trials of ABA001 injection has been approved, and ABA001 injection is intended to be indicated for hypertension.
Beijing Sun-Novo Pharmaceutical Research (688621.SH) announced that the company and its wholly-owned subsidiary Beijing Alna Technology Co., Ltd. have received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration. The clinical trial application for the company's research project ABA001 injection has been approved. The ABA001 injection is intended to be indicated for hypertension.
Related Articles
ZTE Corporation (00763) has not yet repurchased A shares.
PLAYMATES TOYS (00869) bought back 1 million shares for HKD 440,000 on April 2nd.
FUDANZHANGJIANG (01349) subscribed to 3.00 billion yuan of Ping An Bank's structured deposit products.
ZTE Corporation (00763) has not yet repurchased A shares.
PLAYMATES TOYS (00869) bought back 1 million shares for HKD 440,000 on April 2nd.
FUDANZHANGJIANG (01349) subscribed to 3.00 billion yuan of Ping An Bank's structured deposit products.
